Non-classical Monocytes Enhance the Efficacy of Immune Checkpoint Inhibitors on Colon Cancer in a Syngeneic Mouse Model

被引：1

作者：

Goshima, Tsubasa ^{[1
,2
,3
]}

Ieguchi, Katsuaki ^{[1
,4
]}

Onishi, Nobuyuki ^{[1
,4
]}

Shimizu, Takashi ^{[1
,4
]}

Takayanagi, Daisuke ^{[1
,2
,4
]}

Watanabe, Makoto ^{[1
,4
,5
,6
]}

Fujimoto, Yuki ^{[1
,2
,4
]}

Ohkuma, Ryotaro ^{[2
]}

Suzuki, Risako ^{[2
]}

Tsurui, Toshiaki ^{[2
,5
,6
]}

Mura, Emiko ^{[2
]}

Iriguchi, Nana ^{[2
]}

Ishiguro, Tomoyuki ^{[2
]}

Shimokawa, Masahiro ^{[2
]}

Hirasawa, Yuya ^{[2
]}

Kubota, Yutaro ^{[2
]}

Ariizumi, Hirotsugu ^{[2
]}

Horiike, Atsushi ^{[2
]}

Yoshimura, Kiyoshi ^{[2
,4
,7
]}

Tsuji, Mayumi ^{[6
]}

Kiuchi, Yuji ^{[5
,6
]}

Kobayashi, Shinichi ^{[4
]}

Fujishiro, Jun ^{[3
]}

Hoffman, Robert M. ^{[8
,9
]}

Tsunoda, Takuya ^{[2
]}

Wada, Satoshi ^{[1
,2
,4
]}

机构：

[1] Showa Univ, Clin Res Inst Clin Pharmacol & Therapeut, Dept Clin Diagnost Oncol, Tokyo, Japan

[2] Showa Univ, Sch Med, Dept Med, Div Med Oncol, Tokyo, Japan

[3] Univ Tokyo Hosp, Dept Pediat Surg, Tokyo, Japan

[4] Showa Univ, Clin Res Inst Clin Pharmacol & Therapeut, Tokyo, Japan

[5] Showa Univ, Sch Med, Dept Pharmacol, Tokyo, Japan

[6] Showa Univ, Pharmacol Res Ctr, Tokyo, Japan

[7] Showa Univ, Clin Res Inst Clin Pharmacol & Therapeut, Dept Clin ImmunoOncol, Tokyo, Japan

[8] AntiCancer Inc, San Diego, CA USA

[9] Univ Calif San Diego, Dept Surg, San Diego, CA USA

来源：

ANTICANCER RESEARCH | 2024年 / 44卷 / 01期

关键词：

Immune checkpoint inhibitor; non-classical monocyte; flow cytometry; overall survival; MICROSATELLITE INSTABILITY;

D O I：

10.21873/anticanres.16784

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background/Aim: The response rate to immune checkpoint inhibitors (ICIs) is approximately 10%-30% and only in a few cancer types. In the present study, we determined whether non-classical monocytes (NCMs) could enhance ICI efficacy in colon cancer using a syngeneic mouse model. Materials and Methods: The MC38 C57BL/6 mouse colon cancer model was used. Cells collected from the bone marrow of C57BL/6 mice were cultured, and NCMs were fractionated by cell sorting and administered via the tail veins to the mice implanted with MC38 cells. The anti -mouse PD-L1 antibody was administered three times, and tumor volume and overall survival were observed. Results: More tumors were eradicated and more complete response occurred, after cotreatment with ICIs and NCMs than after treatment with ICIs alone. Moreover, no efficacy was observed when NCMs were administered alone. Conclusion: NCMs enhance ICI efficacy. The underlying mechanisms and clinical applications will be studied in the future.

引用

页码：23 / 29

页数：7

共 50 条

[41] Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
Khaddour, Karam
Gomez-Perez, Sandra L.
Jain, Nikita
Patel, Jyoti D.
Boumber, Yanis
FRONTIERS IN ONCOLOGY, 2020, 10
[42] Immunomodulatory Effects of Cryoablation Combined With Immune Checkpoint Inhibitors in a Murine Lung Cancer Model
Yamauchi, Y.
Yamamoto, Y.
Yokote, F.
Dejima, H.
Saito, Y.
Sakao, Y.
Kawamura, M.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S568 - S568
[43] Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer
Yan, Chi
Yang, Jinming
Saleh, Nabil
Chen, Sheau-Chiann
Ayers, Gregory D.
Abramson, Vandana G.
Mayer, Ingrid A.
Richmond, Ann
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (10)
[44] Attribution of value for combination immune checkpoint inhibitors in non-small cell lung cancer
Zaim, Remziye
Redekop, Ken
Uyl-de Groot, Carin A.
JOURNAL OF CANCER POLICY, 2023, 35
[45] Immune checkpoint inhibitors: Significant advancements in non-small cell lung cancer treatment
Glode, Ashley E.
May, Megan B.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2021, 78 (09) : 769 - 780
[46] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
Wei Yuxi
Xu Yan
Wang Mengzhao
中华医学杂志英文版, 2023, 136 (13)
[47] Immune checkpoint inhibitors for the treatment of non-small cell lung cancer brain metastases
Wei, Yuxi
Xu, Yan
Wang, Mengzhao
CHINESE MEDICAL JOURNAL, 2023, 136 (13) : 1523 - 1531
[48] Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer
Lim, Sung Won
Ahn, Myung-Ju
KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (01): : 50 - 59
[49] Predictive biomarkers of response for immune checkpoint inhibitors in non-small-cell lung cancer
Prelaj, Arsela
Tay, Rebecca
Ferrara, Roberto
Chaput, Nathalie
Besse, Benjamin
Califano, Raffaele
EUROPEAN JOURNAL OF CANCER, 2019, 106 : 144 - 159
[50] The Impact of FGFR3 Alterations on the Tumor Microenvironment and the Efficacy of Immune Checkpoint Inhibitors in Bladder Cancer
Komura, Kazumasa
Hirosuna, Kensuke
Tokushige, Satoshi
Tsujino, Takuya
Nishimura, Kazuki
Ishida, Mitsuaki
Hayashi, Takuo
Ura, Ayako
Ohno, Takaya
Yamazaki, Shogo
Nakamori, Keita
Kinoshita, Shoko
Maenosono, Ryoichi
Ajiro, Masahiko
Yoshikawa, Yuki
Takai, Tomoaki
Tsutsumi, Takeshi
Taniguchi, Kohei
Tanaka, Tomohito
Takahara, Kiyoshi
Konuma, Tsuyoshi
Inamoto, Teruo
Hirose, Yoshinobu
Ono, Fumihito
Shiraishi, Yuichi
Yoshimi, Akihide
Azuma, Haruhito
MOLECULAR CANCER, 2023, 22 (01)

← 1 2 3 4 5 →